Evidence map›Paper›PMID 37380802›Full record

ArticleProstate cancer and prostatic diseases2024

Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer.

Ji Liu, Aimaitiaji Kadier, Yadong Guo, Wentao Zhang, Haotian Chen, Zhijin Zhang, Changcheng Guo, Yue Zhang, Meiyu Bao, Jiang Geng and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ji Liu *Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Aimaitiaji Kadier *Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Yadong Guo *Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Wentao ZhangDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Haotian ChenDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhijin ZhangDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Changcheng GuoDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Yue ZhangDepartment of Central Laboratory, Clinical Medicine Scientific and Technical Innovation Park, Shanghai Tenth People's Hospital, Shanghai, 200435, China.
Meiyu BaoDepartment of Central Laboratory, Clinical Medicine Scientific and Technical Innovation Park, Shanghai Tenth People's Hospital, Shanghai, 200435, China.
Jiang GengDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Junfeng ZhangDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. zhangjunfeng@alumni.tongji.edu.cn.
Shiyu MaoDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. maoshiyu1144@sina.com.ORCID 0000-0003-4652-6828
Xudong YaoDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. yaoxudong1967@163.com.ORCID 0000-0001-7234-3940
Tongji University · CNShanghai Tenth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced prostate cancer (PCa) is often resistant to immunotherapy. In this study, we examined the role of CD276 in mediating immunotherapeutic effects through changes in immune cell infiltration.

methodsUsing transcriptomic and proteomic analyses, CD276 was identified as a potential target for immunotherapy. Subsequent in vivo and in vitro experiments confirmed its role as a potential mediator of immunotherapeutic effects.

resultsMulti-omic analysis suggested that CD276 was identified as a key molecule regulating the immune microenvironment (IM). In vivo experiments revealed that CD276 knockdown was found to enhance CD8

conclusionCD276 was found to inhibit the enrichment of CD8+ T cells in PCa. Thus, CD276 inhibitors may be potential targets for immunotherapy.

Indexed as

B7 AntigensLymphocytes, Tumor-InfiltratingProstatic NeoplasmsTumor MicroenvironmentAnimalsBiomarkers, TumorCD8-Positive T-LymphocytesCell Line, TumorGene Expression Regulation, NeoplasticHumansImmunotherapyMaleMiceProteomicsXenograft Model Antitumor AssaysB7 AntigensBiomarkers, TumorCD276 protein, human

Identifiers

PMID37380802
OpenAlexW4382400944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.